Full-Time

Regional Account Director

Confirmed live in the last 24 hours

Ceribell

Ceribell

201-500 employees

Develops EEG devices for brain activity monitoring

Compensation Overview

$170k/yr

+ OTE + Equity Opportunity + Annual Bonus

Expert

Washington, USA + 3 more

More locations: Oregon, USA | California, USA | Nevada, USA

In Person

Candidates must be located near a major airport in the specified states.

Category
Customer Success
Sales & Account Management
Required Skills
Management
Requirements
  • Minimum of 10+ years of recent medical sales experience
  • 10+ years of management experience
  • Proven ability to effectively engage with multiple key stakeholders, including physicians, hospital management, and administration
  • Excellent communicator with strong relationship-building skills
  • Highly organized and capable of prioritizing strategically
  • Thrives in a fast-paced team environment with an entrepreneurial spirit
Responsibilities
  • Implement strategies to introduce new Ceribell products and technologies to existing customers
  • Drive initiatives to expand departmental usage and facilitate upgrades within the existing hospital customer install base
  • Collaborate with the team to ensure successful launches of new accounts by providing guidance and support
  • Be the primary point of contact for customers throughout their Ceribell journey, from purchase through integration and ongoing usage
  • Foster strong relationships with customers, gaining an in-depth understanding of their workflows and needs
  • Ensure adherence to all relevant laws, regulations, and Ceribell policies in all interactions and transactions
  • Work closely with cross-functional teams to align efforts and achieve Ceribell's strategic objectives
  • Collaborate to ensure the successful deployment of Ceribell products at customer locations
  • Build, lead, and manage the CAM teams within the assigned region to achieve organizational goals and objectives
Desired Qualifications
  • Critical care, startup, or industry experience as an RN supporting sales teams is a plus
  • Experience with hospital-wide committee membership is a plus
  • Start-up experience or familiarity with disruptive technology, medical device experience, clinical experience in a neuro ICU, and prior sales experience are all considered advantageous

Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data on brain activity, which is essential for diagnosing and treating neurological conditions, particularly in urgent situations like Nonconvulsive Status Epilepticus (NCSE). Unlike some other medical devices, the Ceribell EEG Recorder does not provide diagnostic conclusions or automated alerts; instead, it serves as a tool for healthcare professionals to collect data for interpretation. Ceribell generates revenue by selling these devices to healthcare providers, adhering to regulations that require physician orders for their use. The company's goal is to enhance the speed and effectiveness of treatment for patients experiencing critical neurological events.

Company Size

201-500

Company Stage

Series C

Total Funding

$171M

Headquarters

Mountain View, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-powered EEG systems reduce diagnosis time by 50%, aiding rapid treatment.
  • Ceribell's IPO raised $180 million, indicating strong investor interest.
  • The demand for point-of-care diagnostic tools is increasing in hospitals.

What critics are saying

  • Increased competition from emerging EEG technologies may impact Ceribell's market share.
  • Potential challenges in scaling production due to supply chain constraints.
  • Recent earnings report missing estimates could affect investor confidence.

What makes Ceribell unique

  • Ceribell's EEG system is FDA cleared and requires no specialist interpreter.
  • The Brain Stethoscope converts brainwaves to sound for easy seizure detection.
  • Ceribell's EEG setup takes only 6 minutes, enhancing time-critical treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Holidays

Parental Leave

Annual Bonus Opportunity

Company Equity

Phone/Internet Stipend

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

4%
GlobeNewswire
May 20th, 2025
Ceribell To Participate In The William Blair 45Th Annual Growth Stock Conference

SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m

MarketBeat
May 11th, 2025
Barclays PLC Makes New Investment in CeriBell (NASDAQ:CBLL)

Barclays PLC makes new Investment in CeriBell (NASDAQ:CBLL).

Zolmax
Apr 8th, 2025
CeriBell's $180M Lock-Up Expires Tomorrow

CeriBell's (NASDAQ:CBLL) lock-up period ends on April 9th, allowing major shareholders and insiders to trade shares. The company issued 10,606,060 shares in its IPO on October 11th, raising $180 million at $17 per share. Analysts have given CBLL a consensus "Buy" rating with a $32.50 price target. The stock opened at $18.19, with a 52-week range of $17.24 to $32.75. Recent earnings missed estimates, reporting a loss of $0.40 per share on $18.53 million revenue.

BioSpace
Nov 20th, 2024
Ceribell Appoints Kristie Rodenbush As Chief People Officer And Brian Price As Senior Vice President Of Marketing

—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms

Fierce Biotech
Oct 15th, 2024
Ceribell CEO Jane Chao explains why now was the time for its upsized IPO

Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.